Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

MiR-130b inhibits proliferation and induces apoptosis of gastric cancer cells via CYLD

Authors: Baoyou Sun, Lei Li, Wendong Ma, Shikang Wang, Chunjin Huang

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

A role of microRNA-130b (miR-130b) in the carcinogenesis of gastric cancer remains undetermined. In this study, we studied the effects and mechanism of miR-130b to the gastric cell proliferation and apoptosis. We found that the levels of miR-130b significantly up-regulated in gastric cancer tissue, compared to the paired adjacent non-tumor gastric tissue. The miR-130b levels in gastric cancer cell lines were significantly higher than those in control normal gastric tissues. Transfection with the miR-130b mimic enhanced the cell proliferation and suppressed cell apoptosis in gastric cancer cells, while transfection with the anti-sense of miR-130b (anti-miR-130b) suppressed cell proliferation and induced cell apoptosis in gastric cancer cells. Bioinformatics analyses showed that cylindromatosis gene (CYLD) was a potential target gene of miR-130b. The luciferase activity assay and western blot verified that miR-130b targeted CYLD messenger RNA (mRNA) to modulate its protein levels. Together, our study suggests that aberrantly expressed miR-130b may regulate cell apoptosis and proliferation of human gastric cancer cells via CYLD, which appears to be a promising therapeutic target for gastric cancer.
Literature
1.
Wu W, Ding H, Cao J, Zhang W. FBXL5 inhibits metastasis of gastric cancer through suppressing Snail1. Cell Physiol Biochem. 2015;35:1764–72.CrossRefPubMed
2.
Liu G, Jiang C, Li D, Wang R, Wang W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. Tumour Biol. 2014;35:9801–6.CrossRefPubMed
3.
Mao D, Zhang Y, Lu H, Zhang H. Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment. Tumour Biol. 2014;35:8217–23.CrossRefPubMed
4.
Ye Y, Zhou X, Li X, Tang Y, Sun Y, Fang J. Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via downregulation of MMP7 and MMP13. Tumour Biol. 2014;35:10891–6.CrossRefPubMed
5.
Hayashi M, Jono H, Shinriki S, Nakamura T, Guo J, Sueta A, et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat. 2014;143:447–57.CrossRefPubMed
6.
Gautheron J, Luedde T. A novel player in inflammation and cancer: the deubiquitinase CYLD controls HCC development. J Hepatol. 2012;57:937–9.CrossRefPubMed
7.
Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell. 2012;21:738–50.CrossRefPubMed
8.
9.
Deng LL, Shao YX, Lv HF, Deng HB, Lv FZ. Over-expressing CYLD augments antitumor activity of trail by inhibiting the NF-kappaB survival signaling in lung cancer cells. Neoplasma. 2012;59:18–29.CrossRefPubMed
10.
Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell. 2009;34:461–72.CrossRefPubMedPubMedCentral
11.
Mei Q, Li F, Quan H, Liu Y, Xu H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. Cancer Sci. 2014;105:755–62.CrossRefPubMedPubMedCentral
12.
Chang Y, Zhao Y, Gu W, Cao Y, Wang S, Pang J, et al. Bufalin inhibits the differentiation and proliferation of cancer stem cells derived from primary osteosarcoma cells through miR-148a. Cell Physiol Biochem. 2015;36:1186–96.CrossRefPubMed
13.
Song W, Li Q, Wang L, Wang L. Modulation of foxo1 expression by miR-21 to promote growth of pancreatic ductal adenocarcinoma. Cell Physiol Biochem. 2015;35:184–90.CrossRefPubMed
14.
Jin Y, Lu J, Wen J, Shen Y, Wen X. Regulation of growth of human bladder cancer by miR-192. Tumour Biol. 2015;36:3791–7.CrossRefPubMed
15.
Wang F, Xiao W, Sun J, Han D, Zhu Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. Tumour Biol. 2014;35:8653–8.CrossRefPubMed
16.
Wang Q, Cai J, Wang J, Xiong C, Zhao J. MiR-143 inhibits EGFR-signaling-dependent osteosarcoma invasion. Tumour Biol. 2014;35:12743–8.CrossRefPubMed
17.
Zhang J, Wang S, Lu L, Wei G. MiR99a modulates MMP7 and MMP13 to regulate invasiveness of Kaposi’s sarcoma. Tumour Biol. 2014;35:12567–73.CrossRefPubMed
18.
Chen B, Hou Z, Li C, Tong Y. MiRNA-494 inhibits metastasis of cervical cancer through Pttg1. Tumour Biol. 2015;36:7143–9.CrossRefPubMed
19.
Li N, Yang L, Wang H, Yi T, Jia X, Chen C, et al. MiR-130b and miR-374a function as novel regulators of cisplatin resistance in human ovarian cancer A2780 cells. PLoS One. 2015;10, e0128886.CrossRefPubMedPubMedCentral
20.
Zhou YM, Liu J, Sun W. MiR-130b overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 2014;15:1391–6.CrossRefPubMed
21.
Boll K, Reiche K, Kasack K, Morbt N, Kretzschmar AK, Tomm JM, et al. MiR-130b, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene. 2013;32:277–85.CrossRefPubMed
22.
Acunzo M, Visone R, Romano G, Veronese A, Lovat F, Palmieri D, et al. MiR-130b targets met and induces trail-sensitivity in NSCLC by downregulating miR-221 and 222. Oncogene. 2012;31:634–42.PubMed
23.
Zhu X, Zhao H, Lin Z, Zhang G. Functional studies of miR-130b on the inhibitory pathways of apoptosis in patients with chronic myeloid leukemia. Cancer Gene Ther 2015.
24.
Zhang X, Huang L, Zhao Y, Tan W. Downregulation of miR-130b contributes to cisplatin resistance in ovarian cancer cells by targeting x-linked inhibitor of apoptosis (XIAP) directly. Acta Biochim Biophys Sin (Shanghai). 2013;45:995–1001.CrossRef
25.
Yang F, Miao L, Mei Y, Wu M. Retinoic acid-induced HOXA5 expression is co-regulated by HuR and miR-130b. Cell Signal. 2013;25:1476–85.CrossRefPubMed
26.
Liang HL, Hu AP, Li SL, Xie JP, Ma QZ, Liu JY. MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev. 2015;16:2397–402.CrossRefPubMed
27.
Li D, Jian W, Wei C, Song H, Gu Y, Luo Y, et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. Int J Clin Exp Pathol. 2014;7:7672–80.PubMedPubMedCentral
28.
Jiang H, Yu WW, Wang LL, Peng Y. MiR-130b acts as a potential diagnostic biomarker and promotes gastric cancer migration, invasion and proliferation by targeting RUNX3. Oncol Rep. 2015;34:1153–61.PubMedPubMedCentral
Metadata
Title
MiR-130b inhibits proliferation and induces apoptosis of gastric cancer cells via CYLD
Authors
Baoyou Sun
Lei Li
Wendong Ma
Shikang Wang
Chunjin Huang
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4632-3

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

Contributions of phosphatidylserine-positive platelets and leukocytes and microparticles to hypercoagulable state in gastric cancer patients

Original Article

Expression of cancer-associated fibroblast-related proteins in thyroid papillary carcinoma

Original Article

MicroRNA-128 inhibits EMT of human osteosarcoma cells by directly targeting integrin α2

Original Article

Prognostic value of ABO blood group in patients with early stage cervical cancer treated with radical hysterectomy with pelvic node dissection

Erratum

Erratum to: Epigenetic downregulated ITGBL1 promotes non-small cell lung cancer cell invasion through Wnt/PCP signaling

Original Article

RETRACTED ARTICLE: Let-7a suppresses glioma cell proliferation and invasion through TGF-β/Smad3 signaling pathway by targeting HMGA2
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits